AXSM Axsome Therapeutics Inc
Company Analysis
Latest News
🔴 Axsome Therapeutics is trading 4.2% down amid biotech and broader market weakness
Axsome Therapeutics is trading 4.24% lower at $149.46 on October 23, 2026, amid biotech and broader market weakness; no clear company-specific catalyst has...
🟢 Axsome Therapeutics is trading 5% up with no company-specific catalyst identified
Axsome Therapeutics is trading at $163.88, up 5.18%; no company-specific catalyst for the October 20 move surfaced in the search. - The latest company update...
🟢 Axsome Therapeutics is trading 4.52% up as RBC says Auvelity trends may be seasonal
Axsome Therapeutics is trading 4.52% up at $169.55 on October 15, rebounding after a sharp recent decline as RBC reiterated its Outperform rating and $295...
Axsome Therapeutics: RBC Reaffirms $295 Target After 28% Slide
RBC Capital reiterated its Outperform rating on Axsome Therapeutics and maintained its $295.00 price target. The stock fell roughly 28% over the past month,...
🟢 Axsome Therapeutics is trading 4.3% up
Axsome Therapeutics is trading 4.34% higher at $163.10 on October 14, 2026, with no clear company-specific catalyst identified. - The stock rebounded after...
🔴 Axsome Therapeutics is trading 4.1% down today after 12 consecutive down sessions
Axsome Therapeutics is trading 4.14% down at $159.13 on October 13, 2026, with no clear company-specific announcement identified to explain the intraday...
🟢 Axsome Therapeutics is trading 4.75% up in pre-market with no clear catalyst identified
Axsome Therapeutics is trading at $176.35, up 4.75%, in pre-market; the reason for the move remains unclear. - No clear company-specific announcement...
🟢 Axsome Therapeutics is trading 13.7% up in after-hours trading with no clear company-specific explanation reported
Axsome Therapeutics is trading at $191.41, up 13.70%, with no clear company-specific announcement explaining the after-hours jump in available October 9...
🔴 Axsome Therapeutics is trading 4.3% down
Axsome Therapeutics is trading 4.3% lower at $169.54, with broader biotechnology weakness potentially contributing. - The XBI biotechnology ETF is down...
🔴 Axsome Therapeutics is trading 4.4% down today with no confirmed direct catalyst
Axsome Therapeutics is trading 4.4% lower at $185.34, with no confirmed direct catalyst identified for the decline. - A September 29 Deutsche Bank update...
🔴 Axsome Therapeutics is trading 4.3% down today as rising oil and Treasury yields pressure equities
Axsome Therapeutics is trading at $194.39, down 4.29%, amid broad risk-off trading. - No clear company-specific announcement or catalyst was identified for...
🔴 Axsome Therapeutics is trading 4.19% down in pre-market; immediate cause remains unclear
Axsome Therapeutics is trading 4.19% down at $196.87 in pre-market, with no clear company-specific catalyst identified for the September 22, 2026, decline. -...
Axsome Unveils New Depression and Alzheimer's Data, Expanding CNS Portfolio
Axsome Therapeutics presented new clinical data for major depressive disorder and Alzheimer's disease agitation at Psych Congress 2026. The company showcased...
🟢 Axsome Therapeutics is trading 4.04% up today after September 15 drop
Axsome Therapeutics is trading at $212.31, up +4.04%, rebounding after falling 5.78% on September 15. - Axsome is presenting at the H.C. Wainwright Global...
🔴 Axsome Therapeutics is trading 4.12% down today as biotech stocks slide
Axsome Therapeutics is trading 4.12% down now at $207.66, with the decline appearing primarily tied to biotechnology-sector weakness and broader market...
Axsome Therapeutics Surges, Driven by Record Weekly Auvelity Prescriptions
Axsome Therapeutics' stock price rose significantly on Friday, September 11. Record-high weekly prescriptions for the drug Auvelity drove the market...
🟢 Axsome Therapeutics is trading 7.17% up today amid market relief after in-line August CPI
Axsome Therapeutics is trading at $226.25, up +7.17%, primarily driven by global market sentiment after August CPI matched expectations. - No clear...
Axsome Therapeutics Initiates Phase 3 Trial for Smoking Cessation Drug AXS-05
Axsome Therapeutics dosed the first patient in its SUMMIT Phase 3 clinical trial. This trial evaluates AXS-05 as a potential smoking cessation treatment. The...
Axsome Therapeutics Attracts OMERS Stake, Driven by Surging Auvelity Sales
OMERS Administration Corp purchased 50,671 shares of Axsome Therapeutics, Inc. The new position is valued at approximately $12.4 million according to a recent...
🔴 Axsome Therapeutics is trading 4.2% down today amid biotech profit-taking
Axsome Therapeutics is trading 4.2% down at $209.04, mainly amid biotechnology profit-taking and broader risk-off trading. - No fresh company-specific...